193 related articles for article (PubMed ID: 20148906)
1. Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
Berberoglu Z; Yazici AC; Demirag NG
Clin Endocrinol (Oxf); 2010 Sep; 73(3):305-12. PubMed ID: 20148906
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women.
Berberoglu Z; Gursoy A; Bayraktar N; Yazici AC; Bascil Tutuncu N; Guvener Demirag N
J Clin Endocrinol Metab; 2007 Sep; 92(9):3523-30. PubMed ID: 17595249
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
Sorocéanu MA; Miao D; Bai XY; Su H; Goltzman D; Karaplis AC
J Endocrinol; 2004 Oct; 183(1):203-16. PubMed ID: 15525588
[TBL] [Abstract][Full Text] [Related]
4. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
Rejnmark L; Buus NH; Vestergaard P; Heickendorff L; Andreasen F; Larsen ML; Mosekilde L
J Bone Miner Res; 2004 May; 19(5):737-44. PubMed ID: 15068496
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
Uretmen S; Gol M; Cimrin D; Irmak E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
[TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
[TBL] [Abstract][Full Text] [Related]
8. Effects of thiazolidinediones on bone loss and fracture.
Murphy CE; Rodgers PT
Ann Pharmacother; 2007 Dec; 41(12):2014-8. PubMed ID: 17940125
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
Bilezikian JP; Josse RG; Eastell R; Lewiecki EM; Miller CG; Wooddell M; Northcutt AR; Kravitz BG; Paul G; Cobitz AR; Nino AJ; Fitzpatrick LA
J Clin Endocrinol Metab; 2013 Apr; 98(4):1519-28. PubMed ID: 23450056
[TBL] [Abstract][Full Text] [Related]
10. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements.
Akin O; Göl K; Aktürk M; Erkaya S
Gynecol Endocrinol; 2003 Feb; 17(1):19-29. PubMed ID: 12724015
[TBL] [Abstract][Full Text] [Related]
12. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
13. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
[TBL] [Abstract][Full Text] [Related]
14. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.
Majkić-Singh N; Ilić M; Ignjatović S; Aleksandra-Postić-Grujin
Clin Lab; 2002; 48(7-8):407-13. PubMed ID: 12146575
[TBL] [Abstract][Full Text] [Related]
15. The effect of thiazolidinediones on BMD and osteoporosis.
McDonough AK; Rosenthal RS; Cao X; Saag KG
Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):507-13. PubMed ID: 18695700
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
17. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
Verit FF; Geyikli I; Yazgan P; Celik A
Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
[TBL] [Abstract][Full Text] [Related]
18. Effects of low-dose prednisone on bone metabolism.
Ton FN; Gunawardene SC; Lee H; Neer RM
J Bone Miner Res; 2005 Mar; 20(3):464-70. PubMed ID: 15746991
[TBL] [Abstract][Full Text] [Related]
19. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis.
Jiang LS; Zhang ZM; Jiang SD; Chen WH; Dai LY
J Bone Miner Res; 2008 Apr; 23(4):475-83. PubMed ID: 18052758
[TBL] [Abstract][Full Text] [Related]
20. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
